γ-secretases: from cell biology to therapeutic strategies

The Lancet Neurology

Volumn 9, Issue 2, 2010, Pages 215-226

  Bergmans, Bruno A ^a,b   De Strooper, Bart ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; G PROTEIN COUPLED RECEPTOR; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NERVE CELL ADHESION MOLECULE; NEU DIFFERENTIATION FACTOR; NEUROTROPHIN RECEPTOR P75; NOTCH RECEPTOR; PRESENILIN 1; PRESENILIN 2; TARENFLURBIL; UVOMORULIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CALCIUM CELL LEVEL; CYTOLOGY; DAILY LIFE ACTIVITY; DIFFUSE LEWY BODY DISEASE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC HETEROGENEITY; HETEROZYGOTE; HUMAN; MOLECULAR BIOLOGY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPASTIC PARAPLEGIA;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL BIOLOGY; ENZYME INHIBITORS; HUMANS; MUTATION; NERVOUS SYSTEM DISEASES; PRESENILINS;

EID: 76449085569     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70332-1     Document Type: Review

References (171)

1. Sherrington R., Rogaev E.I., Liang Y., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (1995) 754-760
2. Levy-Lahad E., Wasco W., Poorkaj P., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
3. Rogaev E.I., Sherrington R., Rogaeva E.A., et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376 (1995) 775-778
4. Clark R.F., Hutton M., Fuldner M., et al. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 11 (1995) 219-222
5. Alzheimer Research Forum. The presenilin-1 mutations. http://www.alzforum.org/res/com/mut/pre/table1.asp (accessed Nov 7, 2009).
6. Cruts M., van Duijn C.M., Backhovens H., et al. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 7 (1998) 43-51
7. Raux G., Guyant-Marechal L., Martin C., et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet 42 (2005) 793-795
8. Lleo A., Blesa R., Queralt R., et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 59 (2002) 1759-1763
9. Janssen J.C., Beck J.A., Campbell T.A., et al. Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 60 (2003) 235-239
10. Alzheimer Research Forum. Presenilin mutations directory. http://www.alzforum.org/res/com/mut/pre/default.asp (accessed Nov 7, 2009).
11. Ott A., Breteler M.M., van Harskamp F., et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. Am J Epidemiol 147 (1998) 574-580
12. Cruts M., and Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat 11 (1998) 183-190
13. Strittmatter W.J., Saunders A.M., Schmechel D., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90 (1993) 1977-1981
14. Corder E.H., Saunders A.M., Strittmatter W.J., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
15. Saunders A., Strittmatter W.J., Schmechel D., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
16. Lambert J.-C., Heath S., Even G., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 (2009) 1094-1099
17. Harold D., Abraham R., Hollingworth P., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 (2009) 1088-1093
18. De Strooper B., Annaert W., Cupers P., et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398 (1999) 518-522
19. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
20. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron 38 (2003) 9-12
21. Spasic D., Tolia A., Dillen K., et al. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem 281 (2006) 26569-26577
22. De Strooper B., Saftig P., Craessaerts K., et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 (1998) 387-390
23. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., and Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398 (1999) 513-517
24. Struhl G., and Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. Mol Cell 6 (2000) 625-663
25. Golde T.E., and Eckman C.B. Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. Sci STKE 2003 (2003) RE4
26. Jung K.M. Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J Biol Chem 278 (2003) 42161-42169
27. Kim D.Y., Ingano L., Carey B.W., Pettingell W.H., and Kovacs D.M. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem 280 (2005) 23251-23261
28. Taniguchi Y., Kim S.H., and Sisodia S.S. Presenilin-dependent gamma-secretase processing of deleted in colorectal cancer (DCC). J Biol Chem 278 (2003) 30425-30428
29. Dejaegere T., Serneels L., Schäfer M.K., et al. Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci USA 105 (2008) 9775-9780
30. Kopan R., and Ilagan M.X. Gamma-secretase: proteasome of the membrane?. Nat Rev Mol Cell Biol 5 (2004) 499-504
31. Willem M., Garratt A.N., Novak B., et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 (2006) 664-666
32. Consuelo W.-B., Wei L., Debbie F.L., et al. A novel missense mutation in the transmembrane domain of neuregulin 1 is associated with schizophrenia. Biol Psychiatry 60 (2006) 548-553
33. Stefansson H., Sigurdsson E., Steinthorsdottir V., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 (2002) 877-892
34. Rodney C.P.G., Rodney T.P., Howard W., et al. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatric Genet 139B (2005) 28-32
35. Vassar R., Bennett B.D., Babu-Khan S., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
36. Evin G. Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer's treatment. Exp Rev Neurother 8 (2008) 1611-1613
37. Wolfe M.S. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45 (2006) 7931-7939
38. Selkoe D.J., and Wolfe M.S. Presenilin: running with scissors in the membrane. Cell 131 (2007) 215-221
39. Scheuner D., Eckman C., Jensen M., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 (1996) 864-870
40. Pan D., and Rubin G.M. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell 90 (1997) 271-280
41. Wen C., Metzstein M.M., and Greenwald I. SUP-17, a Caenorhabditis elegans ADAM protein related to Drosophila KUZBANIAN, and its role in LIN-12/NOTCH signalling. Development 124 (1997) 4759-4767
42. Hartmann D., de Strooper B., Serneels L., et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11 (2002) 2615-2624
43. Brou C., Logeat F., Gupta N., et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5 (2000) 207-216
44. Struhl G., and Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398 (1999) 522-525
45. Kopan R., and Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 14 (2000) 2799-2806
46. Kopan R., and Ilagan M.X.G. Gamma-secretase: proteasome of the membrane?. Nat Rev Mol Cell Biol 5 (2004) 499-504
47. Louvi A., and Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci 7 (2006) 93-102
48. Palomero T., and Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res 14 (2008) 5314-5317
49. Geling A., Steiner H., Willem M., Bally-Cuif L., and Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 3 (2002) 688-694
50. Micchelli C.A., Esler W.P., Kimberly W.T., et al. G-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J (November 1, 2002) 10.1096/fj.02-0394fje
51. Tournoy J., Bossuyt X., Snellinx A., et al. Partial loss of presenilins causes seborrheic keratosis and autoimmune disease in mice. Hum Mol Genet 13 (2004) 1321-1331
52. DeAngelo D. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 24 (2006) 6585
53. Wong G.T., Manfra D., Poulet F.M., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
54. van Es J.H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 (2005) 959-963
55. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126 (2006) 981-993
56. Chan S.L., Mayne M., Holden C.P., Geiger J.D., and Mattson M.P. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 275 (2000) 18195-18200
57. Chakroborty S., Goussakov I., Miller M.B., and Stutzmann G.E. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci 29 (2009) 9458-9470
58. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58 (2008) 871-883
59. 2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 26 (2006) 5180-5189
60. Bezprozvanny I., and Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31 (2008) 454-463
61. 2+ leak function of presenilin 1. J Clin Investig 117 (2007) 1230-1239
62. Zhang C., Wu B., Beglopoulos V., et al. Presenilins are essential for regulating neurotransmitter release. Nature 460 (2009) 632-636
63. Saura C., Choi S.-Y., Beglopoulos V., et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42 (2004) 23-36
64. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8 (2007) 141-146
65. Wolfe M.S. When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8 (2007) 136-140
66. Bentahir M., Nyabi O., Jan V., et al. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96 (2006) 732-742
67. Song W., Nadeau P., Yuan M., Yang X., Shen J., and Yankner B.A. Proteolytic release and nuclear translocation of Notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations. Proc Natl Acad Sci USA 96 (1999) 6959-6963
68. Schroeter E.H., Ilagan M.X., Brunkan A.L., et al. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA 100 (2003) 13075-13080
69. Kumar-Singh S., Theuns J., van Broeck B., et al. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Hum Mutat 27 (2006) 686-695
70. Galvan V., Gorostiza O.F., Banwait S., et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci USA 103 (2006) 7130-7135
71. Walsh D.M., Klyubin I., Fadeeva J.V., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
72. Lesné S., Koh M.T., Kotilinek L., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
73. Citron M., Oltersdorf T., Haass C., et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360 (1992) 672-674
74. Serneels L., Van Biervliet J., Craessaerts K., et al. Gamma-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324 (2009) 639-642
75. Li T., Wen H., Brayton C., et al. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27 (2007) 10849-10859
76. Nishitomi K., Sakaguchi G., Horikoshi Y., et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem 99 (2006) 1555-1563
77. Bernardi L., Tomaino C., Anfossi M., et al. Late onset familial Alzheimer's disease: novel presenilin 2 mutation and PS1 E318G polymorphism. J Neurol 255 (2008) 604-606
78. Sherrington R., Froelich S., Sorbi S., et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 5 (1996) 985-988
79. Lai M.T., Chen E., Crouthamel M.C., et al. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem 8 (2003) 8
80. Zhao B., Yu M., Neitzel M., et al. Identification of gamma-secretase inhibitor potency determinants on presenilin. J Biol Chem 283 (2008) 2927-2938
81. Van Broeckhoven C., Backhovens H., Cruts M., et al. APOE genotype does not modulate age of onset in families with chromosome 14 encoded Alzheimer's disease. Neurosci Lett 169 (1994) 179-180
82. Lendon C.L., Martinez A., Behrens I.M., et al. E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles. Hum Mutat 10 (1997) 186-195
83. Portet F., Dauvilliers Y., Campion D., et al. Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu). Neurology 61 (2003) 1136-1137
84. Payami H.P., Schellenberg G.D.P., Zareparsi S.M., et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 49 (1997) 512-518
85. Kwok J.B.J., Taddei K., Hallupp M., et al. Two novel (M233T and [rho]278T) presenilin-1 mutations in early-onset Alzheimer's disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport 8 (1997) 1537-1542
86. Verkkoniemi A., Somer M., Rinne J.O., et al. Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology 54 (2000) 1103-1109
87. Crook R., Verkkoniemi A., Perez-Tur J., et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 4 (1998) 452-455
88. Houlden H., Baker M., McGowan E., et al. Variant Alzheimer's disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol 48 (2000) 806-808
89. Steiner H., Revesz T., Neumann M., et al. A pathogenic presenilin-1 deletion causes abberrant Abeta42 production in the absence of congophilic amyloid plaques. J Biol Chem 276 (2001) 7233-7239
90. Ataka S., Tomiyama T., Takuma H., et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol 61 (2004) 1773-1776
91. Rudzinski L.A., Fletcher R.M., Dickson D.W., et al. Early onset familial Alzheimer disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord 22 (2008) 299-307
92. Finckh U., Müller-Thomsen T., Mann U., et al. High prevalence of pathogenic mutations in patients with early onset dementia detected by sequence analyses of four different genes. Am J Hum Genet 66 (2000) 110-117
93. Hattori S., Sakuma K., Wakutani Y., et al. A novel presenilin 1 mutation (Y154N) in a patient with early onset Alzheimer's disease with spastic paraparesis. Neurosci Lett 368 (2004) 319-322
94. Moretti P., Lieberman A.P., Wilde E.A., et al. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology 62 (2004) 1865-1868
95. Moehlmann T., Winkler E., Xia X., et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on AB42 production. Proc Natl Acad Sci USA 99 (2002) 8025-8030
96. Sodeyama N., Iwata T., Ishikawa K., et al. Very early onset Alzheimer's disease with spastic paraparesis associated with a novel presenilin 1 mutation (Phe237Ile). J Neurol Neurosurg Psychiatry 71 (2001) 556-557
97. Judith M., Kevin T., Domizio S., et al. Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol Aging 24 (2003) 655-662
98. Caballero P., Boguna C., Correa E.M., Candela M.S., and Alonso C.M. A novel presenilin 1 mutation (V261L) associated with presenile Alzheimer's disease and spastic paraparesis. Eur J Neurol 15 (2008) 991-994
99. Farlow M., Murrell J., Unverzagt F., et al. Familial Alzheimer's disease with spastic paraparesis associated with a mutation at codon 261 of the presenilin 1 gene. In: Iqbal K., Sisodia S.S., and Winblad B. (Eds). Alzheimer's disease: advances in etiology, pathogenesis and therapeutics (2001), John Wiley, Chichester 53-60
100. Jacquemont M.L., Campion D., Hahn V., et al. Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer's disease. J Med Genet 39 (2002) e2
101. Matsubara-Tsutsui M., Yasuda M., Yamagata H., et al. Molecular evidence of presenilin 1 mutation in familial early onset dementia. Am J Med Genet 114 (2002) 292-298
102. Assini A., Terreni L., Borghi R., et al. Pure spastic paraparesis associated with a novel presenilin 1 R278K mutation. Neurology 60 (2003) 150
103. Raman A., Lin X., Suri M., Hewitt M., Constantinescu C.S., and Phillips M.F. A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer's disease and spastic paraparesis. J Neurol Sci 260 (2007) 78-82
104. O'Riordan S., McMonagle P., Janssen J.C., et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 59 (2002) 1108-1110
105. Rogaeva E., Bergeron C., Sato C., et al. PS1 Alzheimer's disease family with spastic paraplegia: the search for a gene modifier. Neurology 61 (2003) 1005-1007
106. Tabira T., Chui D., Nakayama H., Kuroda S., and Shibuya M. Alzheimer's disease with spastic paresis and cotton wool type plaques. J Neurosci Res 70 (2002) 367-372
107. Marrosu M.G., Floris G., Costa G., et al. Dementia, pyramidal system involvement, and leukoencephalopathy with a presenilin 1 mutation. Neurology 66 (2006) 108-111
108. Brooks W.S., Kwok J.B.J., Kril J.J., et al. Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. Brain 126 (2003) 783-791
109. Smith J., Kwok J., McLean C., et al. Variable phenotype of Alzheimer's disease with spastic paraparesis. Ann Neurol 49 (2001) 125-129
110. Mehrabian S., Traykov L., Rademakers R., et al. A novel PSEN1 mutation in an EOAD family with spastic paraparesis and extrapyramidal signs. Eur J Neurol 11 suppl 2 (2004) 16 (abstr SC123).
111. Yasuda M., Maeda S., Kawamata T., et al. Novel presenilin-1 mutation with widespread cortical amyloid deposition but limited cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 68 (2000) 220-223
112. Atsushi I., Yue-Shan P., Akinori M., et al. A mutant PSEN1 causes dementia with lewy bodies and variant Alzheimer's disease. Ann Neurol 57 (2005) 429-434
113. Larner A., and Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 253 (2006) 139-158
114. Verkkoniemi A., Kalimo H., Paetau A., et al. Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol 60 (2001) 483-492
115. Lazarov O., Morfini G.A., Pigino G., et al. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci 27 (2007) 7011-7020
116. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., and Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23 (2003) 4499-4508
117. Amtul Z., Lewis P.A., Piper S., et al. A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol Dis 9 (2002) 269-273
118. Raux G., Gantier R., Thomas-Anterion C., et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology 55 (2000) 1577-1579
119. Dermaut B., Kumar-Singh S., Engelborghs S., et al. A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann Neurol 55 (2004) 617-626
120. Boeve B.F., Baker M., Dickson D.W., et al. Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain 129 (2006) 3103-3114
121. van der Zee J., Sleegers K., and Broeckhoven C.V. The Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology 71 (2008) 1191-1197
122. Snider B.J., Norton J., Coats M.A., et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 62 (2005) 1821-1830
123. Piscopo P., Marcon G., Piras M.R., et al. A novel PSEN2 mutation associated with a peculiar phenotype. Neurology 70 (2008) 1549-1554
124. Dovey H.F., John V., Anderson J.P., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76 (2001) 173-181
125. Cullion K., Draheim K.M., Hermance N., et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 113 (2009) 6172-6181
126. Engin F., Bertin T., Ma O., et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet 18 (2009) 1464-1470
127. Meng R.D., Shelton C.C., Li Y.-M., et al. Gamma-secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 69 (2009) 573-582
128. Arumugam T.V., Chan S.L., Jo D.-G., et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 12 (2006) 621-623
129. Jurynczyk M., Jurewicz A., Bielecki B., Raine C., and Selmaj K. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol 170 (2005) 3-10
130. Milano J. Modulation of Notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82 (2004) 341-358
131. Searfoss G.H., Jordan W.H., Calligaro D.O., Galbreath E.J., Schirtzinger L.M., and Berridge B.R. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278 (2003) 46107-46116
132. Lewis H.D. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 14 (2007) 209-219
133. Palomero T. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia 20 (2006) 1279-1287
134. Real P.J., and Ferrando A.A. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 23 (2009) 1374-1447
135. Effects of LY450139, on the progression of Alzheimer's disease as compared with placebo (IDENTITY-2). http://www.clinicaltrials.gov/ct2/show/NCT00762411?term=semagacestat &rank=2 (accessed November, 2009).
136. Siemers E.R., Quinn J.F., Kaye J., et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66 (2006) 602-604
137. Fleisher A.S., Raman R., Siemers E.R., et al. Phase 2 safety trial targeting amyloid-beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65 (2008) 1031-1038
138. Siemers E., Skinner M., Dean R.A., et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28 (2005) 126-132
139. Mayer S.C., Kreft A.F., Harrison B., et al. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem 51 (2008) 7348-7351
140. Martone R.L., Zhou H., Atchison K., et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 331 (2009) 598-608
141. Alzheimer Research Forum, Drugs in clinical trials. http://www.alzforum.org/drg/drc/default.asp?type=keyword&keyword=sec retase+inhibitor (accessed Nov 7, 2009).
142. A phase II, multicenter, double blind, placebo-controlled safety, tolerability study of BMS-708163 in patients with mild to moderate Alzheimer's disease. http://www.clinicaltrials.gov/ct2/show/NCT00810147?term=BMS-708163&r ank=2 (accessed Nov 7, 2009).
143. Pui C.-H. T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome. Cancer Cell 15 (2009) 85-87
144. Real P.J., Tosello V., Palomero T., et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15 (2009) 50-58
145. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., and de Stanchina E. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15 (2009) 50-58
146. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
147. Fraering P.C., Ye W., LaVoie M.J., Ostaszewski B.L., Selkoe D.J., and Wolfe M.S. Gamma-secretase substrate selectivity can be modulated directly via interaction with a nucleotide binding site. J Biol Chem 280 (2005) 41987-41996
148. Netzer W.J., Dou F., Cai D., et al. Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci USA 100 (2003) 12444-12449
149. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20 (2000) 5709-5714
150. Kukar T.L., Ladd T.B., Bann M.A., et al. Substrate-targeting gamma-secretase modulators. Nature 453 (2008) 925-929
151. Tabet N., and Feldman H. Indomethacin for Alzheimer's disease. Cochr Database Syst Rev 2 (2002) CD003673.
152. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
153. Hüll M., Berger M., and Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come?. Drugs 66 (2006) 2075-2093
154. Eriksen J.L., Sagi S.A., Smith T.E., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta42 in vivo. J Clin Invest 112 (2003) 440-449
155. Beher D., Clarke E.E., Wrigley J.D.J., et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site: evidence for an allosteric mechanism. J Biol Chem 279 (2004) 43419-43426
156. Morihara T., Chu T., Ubeda O., Beech W., and Cole G.M. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 83 (2002) 1009-1012
157. Ren Z., Schenk D., Basi G.S., and Shapiro I.P. Amyloid-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. J Biol Chem 282 (2007) 35350-35360
158. Kukar T., Prescott S., Eriksen J., et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neuroscience 8 (2007) 54
159. Wilcock G.K., Black S.E., Hendrix S.B., Zavitz K.H., Swabb E.A., and Laughlin M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol 7 (2008) 483-493
160. Green R.C., Schneider L.S., Amato D.A., et al., for the Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302 (2009) 2557-2564
161. Imbimbo B.P., Hutter-Paier B., Villetti G., et al. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol 156 (2009) 982-993
162. Imbimbo B.P., Del Giudice E., Colavito D., et al. 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclop ropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323 (2007) 822-830
163. Hébert S.S., Serneels L., Dejaegere T., et al. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 17 (2004) 260-272
164. Shirotani K., Edbauer D., Prokop S., Haass C., and Steiner H. Identification of distinct gamma-secretase complexes with different APH-1 variants. J Biol Chem 279 (2004) 41340-41345
165. Schroeter E.H. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc Natl Acad Sci USA 100 (2003) 13075-13080
166. Takasugi N., Tomita T., Hayashi I., et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 422 (2003) 438-441
167. Serneels L., Dejaegere T., Craessaerts K., et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA 102 (2005) 1719-1724
168. Ma G., Li T., Price D.L., and Wong P.C. APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. J Neurosci 25 (2005) 192-198
169. Herreman A., Hartmann D., Annaert W., et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci USA 96 (1999) 11872-11877
170. Ni Y.X., Zhao X.H., Bao G.B., et al. Activation of beta-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med 12 (2006) 1390-1396
171. Thathiah A., Spittaels K., Hoffmann M., et al. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 323 (2009) 946-951